What is "venetoclax"

Venetoclax ( INN, trade name Venclexta , previously known as GDC-0199, ABT-199, and RG7601) is a small molecule oral drug being investigated to treat chronic lymphocytic leukemia (CLL). In 2015, the United States Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to venetoclax for patients with CLL who have relapsed or have been refractory to previous treatment and have the 17p deletion genetic mutation.